FTC opens door for Emergent BioSolutions, Inc.'s Trubion acquisition

The U.S. Department of Justice and Federal Trade Commission has granted an early termination of the Hart-Scott-Rodino Antitrust Improvements Act of 1976 waiting period for Emergent BioSolutions, Inc.'s planned acquisition of Trubion Pharmaceuticals, Inc.

The requirement under the merger agreement for the expiration or termination of any waiting period under the HSR Act has been satisfied, Emergent BioSolutions, Inc., announced, but the closing of the transaction, first announced on August 12, remains subject to other conditions in the definitive merger agreement, including approval by Trubion's stockholders.

Trubion, a biopharmaceutical company, is in the process of creating a pipeline of novel protein therapeutic candidates to treat autoimmune and inflammatory diseases and cancers.

The company's stated mission is to develop a variety of first-in-class and best-in-class product candidates that are customized for optimal safety, efficacy and convenience, resulting in improved patient experiences.

Currently, Trubion's product candidates are novel single-chain protection therapeutics designed using its custom drug assembly technology. The company's product pipeline includes CD20-directed SMIP therapeutics, including SBI-087 for autoimmune and inflammatory diseases, which was developed in a collaboration with Pfizer.

Trubion's pipeline also includes TRU-016, a novel CD37-targeted therapy for the treatment of B-cell malignancies developed under the company's collaboration with Abbott.

Trubion is also developing a multi-specific SCORPION technology to target cell-surface molecules and to neutralize soluble ligands.